Sandhu Bimaljit Singh, Sanyal Arun J
Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University Medical Center, MCV Box 980341, Richmond, VA 23298, USA.
Clin Liver Dis. 2005 Nov;9(4):715-32, viii. doi: 10.1016/j.cld.2005.07.008.
Onset of ascites in cirrhosis of the liver is associated with worsened quality of life, increased risk of spontaneous bacterial peritonitis, and renal failure. Portal hypertension produces splanchnic vasodilation that triggers the cascade of events leading to release of Na retentive vasoconstrictor hormones. Management of ascites caused by cirrhosis is based on improving the Na excretion with diuretics and Na restriction in diet. Refractory ascites and hepatorenal syndrome are the complications of ascites that carry a very high mortality. Large volume paracentesis and transjugular intrahepatic porto-systemic shunts are useful in managing patients with refractory ascites. Liver transplant is the only way to improve survival in ascites caused by cirrhosis.
肝硬化腹水的出现与生活质量下降、自发性细菌性腹膜炎风险增加及肾衰竭相关。门静脉高压导致内脏血管扩张,引发一系列事件,导致潴留钠的血管收缩激素释放。肝硬化所致腹水的治疗基于使用利尿剂改善钠排泄及饮食中限制钠摄入。顽固性腹水和肝肾综合征是腹水的并发症,死亡率极高。大量腹腔穿刺放液和经颈静脉肝内门体分流术对治疗顽固性腹水患者有用。肝移植是提高肝硬化所致腹水患者生存率的唯一方法。